查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2028116

短腸症候群市場規模、佔有率、成長及全球產業分析：按類型、應用和地區分類的洞察，2026-2034 年預測

Short Bowel Syndrome Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2026-2034
出版日期: | 出版商: Fortune Business Insights Pvt. Ltd. | 英文 127 Pages | 商品交期: 2-3個工作天內

價格

短腸症候群(SBS) 市場成長要素

受疾病患病率上升、先進治療方法的廣泛應用以及人們對這種罕見胃腸道疾病認知不斷提高的推動，全球短腸症候群（SBS）市場正經歷穩步成長。預計該市場規模在2025年將達到16.5億美元，2026年將成長至18.9億美元，到2034年將達到27億美元，2026年至2034年的複合年成長率（CAGR）為4.57%。

得益於龐大的確診患者群體、健全的保險報銷體係以及創新治療方法的高普及率，預計到2025年，北美將以75.87%的市場佔有率主導全球市場。美國市場為主要貢獻者，預計到2032年將達到19.3億美元。

市場動態

短腸症候群是一種罕見疾病，其特徵是腸道功能障礙，患者嚴重依賴腸外營養（PS）來維持營養。全球範圍內，美國和歐盟五國約有15,000至20,000人受其影響。然而，長期依賴腸外營養會導致肝功能障礙和感染疾病等併發症，並產生高達年度治療費用。

因此，人們對能夠增強腸道吸收、減少腸外營養依賴的先進藥物療法的需求日益成長，尤其是GLP-2類似物。目前，武田藥品工業株式會社的「Gatex（Revestive）」是唯一核准的GLP-2藥物，但仍有多種候選藥物正在研發中。

市場趨勢

影響市場發展的關鍵趨勢之一是從全靜脈營養（TPN）轉向基於GLP-2的治療方法。這些藥物能夠改善患者預後，縮短住院時間，並改善生活品質。

製藥公司正積極投資臨床試驗。例如，Zealand Pharma A/S公司宣布，其長效GLP-2類似物glepaglutide的3期臨床試驗取得了正面成果。同樣，韓美製藥有限公司也正在開發GLP-2候選藥物。

市場成長要素

GLP-2製劑應用範圍擴大

GLP-2療法的應用率正在顯著上升，尤其是在美國和歐洲等已開發市場。在美國，約有18-20%的短腸症候群（SBS）患者正在接受此類藥物治療。減少對靜脈營養的依賴是成長要素。

提高公眾意識和支持計劃

病患團體和醫療機構正積極進行有關嬰兒搖晃症候群（SBS）的宣傳教育活動。因此，全球範圍內的診斷率和治療啟動率都在不斷提高。

擴大研發投資

像 Ironwood Pharmaceuticals 這樣的公司正在大力投資研發下一代治療方法，進一步推動市場擴張。

抑制因子

儘管市場成長強勁，但高昂的治療費用也帶來了挑戰。例如，GLP-2 受體激動劑類藥物（如 Gattex）的年度治療費用可能高達每位患者 20 萬至 30 萬美元，這限制了發展中地區患者獲得治療的機會。

此外，在印度和非洲部分地區，有限的保險報銷制度和較低的意識正在阻礙市場滲透。

細分分析

按類型

到2026年，GLP-2療法將佔市場主導地位，市佔率高達97.01%，這主要得益於已通過核准藥物的供應和強勁的在研產品線。其他細分市場包括生長激素荷爾蒙療法和麩醯胺酸療法。

透過分銷管道

到 2026 年，線上和零售藥局領域將以 60.66% 的市佔率引領市場，這得益於數位化進步和藥品取得更加便利。

區域趨勢

北美洲

預計北美將引領市場，2025年市場規模將達12.5億美元，2026年將達14.5億美元。這一成長是由先進的醫療保健基礎設施和創新治療方法的高滲透率所推動的。

歐洲

在廣泛的臨床研究和有利的治療指南的支持下，預計到 2025 年，歐洲的醫療支出將達到 1.8 億美元。

亞太地區

預計到 2025 年，亞太地區的市場規模將達到 1.7 億美元，由於人們意識的提高和臨床試驗的增加，預計將保持穩定成長。

拉丁美洲、中東和非洲

由於醫療保健服務的改善和對罕見疾病認知的提高，預計這些地區將經歷適度成長。

目錄

第1章：引言

第2章摘要整理

第3章 市場動態

  • 市場促進因素
  • 市場限制因素
  • 市場機遇
  • 市場趨勢

第4章：主要考慮因素

  • 短腸症候群盛行率：按主要國家分類，2025 年
  • 產業重大發展動態：合併、收購、合作等。
  • 新冠疫情對全球市場的影響

第5章：2021-2034年全球短腸症候群市場分析、洞察與預測

  • 市場分析、洞察與預測：按類型
    • GLP-2
    • 生長激素
    • 麩醯胺酸
  • 市場分析、洞察與預測：按分銷管道分類
    • 醫院藥房
    • 網路藥局和實體藥局
  • 市場分析、洞察與預測：按地區分類
    • 北美洲
    • 歐洲
    • 亞太地區
    • 拉丁美洲
    • 中東和非洲

第6章：北美短腸症候群市場分析、洞察與預測（2021-2034年）

  • 國家
    • 美國
    • 加拿大

第7章：歐洲短腸症候群市場分析、洞察與預測（2021-2034年）

  • 國家
    • 英國
    • 德國
    • 法國
    • 西班牙
    • 義大利
    • 其他歐洲國家

第8章：亞太地區短腸症候群市場分析、洞察與預測（2021-2034年）

  • 國家
    • 日本
    • 韓國
    • 澳洲
    • 中國
    • 印度
    • 東南亞
    • 其他亞太國家

第9章：拉丁美洲短腸症候群市場分析、洞察與預測（2021-2034年）

  • 國家
    • 巴西
    • 墨西哥
    • 阿根廷
    • 哥倫比亞
    • 其他拉丁美洲國家

第10章：中東和非洲短腸症候群市場分析、洞察與預測（2021-2034年）

  • 國家
    • 土耳其
    • 沙烏地阿拉伯
    • UAE
    • 其他中東和非洲國家

第11章 競爭分析

  • 全球市佔率分析（2025 年）
  • 公司簡介
    • Takeda Pharmaceutical Company Limited
    • Merck KGaA
    • ZEALAND PHARMA
    • Ironwood
    • Hanmi Pharm. Co., Ltd.
    • Nestle
    • Jaguar Health
    • EnteraBio Ltd.
    • OxThera
Product Code: FBI107071

Growth Factors of short bowel syndrome (SBS) Market

The global short bowel syndrome (SBS) market is witnessing steady growth, driven by rising disease prevalence, increasing adoption of advanced therapies, and growing awareness of rare gastrointestinal disorders. The market size was valued at USD 1.65 billion in 2025 and is projected to grow to USD 1.89 billion in 2026, reaching USD 2.7 billion by 2034, registering a CAGR of 4.57% during 2026-2034.

North America dominated the global market with a 75.87% share in 2025, supported by a large diagnosed patient pool, strong reimbursement systems, and high adoption of innovative therapies. The U.S. market is a key contributor, projected to reach USD 1.93 billion by 2032.

Market Dynamics

Short bowel syndrome is a rare condition associated with intestinal failure, where patients rely heavily on parenteral support (PS) for nutrients. Globally, around 15,000-20,000 patients in the U.S. and EU-5 are affected. However, long-term dependence on parenteral nutrition leads to complications such as liver dysfunction and infections, along with high annual treatment costs ranging from USD 65,000 to USD 320,000.

This has increased the demand for advanced drug therapies, particularly GLP-2 analogs, which enhance intestinal absorption and reduce dependency on parenteral nutrition. Currently, Gattex (Revestive) by Takeda Pharmaceutical Company Limited is the only approved GLP-2 drug, although several pipeline candidates are under development.

Market Trends

A key trend shaping the market is the shift from total parenteral nutrition (TPN) to GLP-2-based therapies. These drugs offer improved patient outcomes, reduced hospitalization, and better quality of life.

Pharmaceutical companies are actively investing in clinical trials. For instance, Zealand Pharma A/S reported positive Phase 3 results for Glepaglutide, a long-acting GLP-2 analog. Similarly, Hanmi Pharm Co., Ltd. is advancing its GLP-2 pipeline candidate.

Market Growth Drivers

Increasing Adoption of GLP-2 Drugs

The penetration of GLP-2 therapies is rising significantly, especially in developed markets such as the U.S. and Europe. Around 18-20% of SBS patients in the U.S. are already treated using these drugs. Their ability to reduce parenteral support dependency is a major growth driver.

Rising Awareness and Support Programs

Organizations such as patient foundations and healthcare bodies are promoting awareness and education regarding SBS. This is improving diagnosis rates and treatment adoption globally.

Growing R&D Investments

Companies like Ironwood Pharmaceuticals are investing heavily in research to develop next-generation therapies, further supporting market expansion.

Restraining Factors

Despite positive growth, the market faces challenges due to high treatment costs. The annual cost of GLP-2 drugs such as Gattex can range between USD 200,000 and USD 300,000 per patient, limiting accessibility in developing regions.

Additionally, limited reimbursement policies and low awareness in countries such as India and parts of Africa restrict market penetration.

Segmentation Analysis

By Type

The GLP-2 segment dominated the market in 2026, accounting for 97.01% share, due to the availability of approved drugs and strong pipeline development. Other segments include growth hormone and glutamine therapies.

By Distribution Channel

The online & retail pharmacy segment led the market with a 60.66% share in 2026, driven by increasing digital adoption and easy accessibility of medications.

Regional Insights

North America

North America led the market with USD 1.25 billion in 2025 and is expected to reach USD 1.45 billion in 2026. Growth is driven by advanced healthcare infrastructure and high adoption of innovative therapies.

Europe

Europe accounted for USD 0.18 billion in 2025, supported by strong clinical research and favorable treatment guidelines.

Asia Pacific

Asia Pacific recorded USD 0.17 billion in 2025 and is expected to grow steadily due to rising awareness and increasing clinical trials.

Latin America & Middle East & Africa

These regions show gradual growth due to improving healthcare access and increasing awareness of rare diseases.

Competitive Landscape

The market is highly concentrated, with Takeda Pharmaceutical Company Limited leading due to its strong product portfolio. Other key players include Zealand Pharma A/S, Ironwood Pharmaceuticals, Merck KGaA, and Nestle Health Science.

These companies are focusing on collaborations, clinical trials, and innovative drug development to strengthen their market position.

Conclusion

In conclusion, the short bowel syndrome market is poised for steady growth, rising from USD 1.65 billion in 2025 to USD 2.7 billion by 2034. The increasing adoption of GLP-2 therapies, growing awareness, and strong R&D investments are key factors driving this expansion. However, high treatment costs and limited access in developing regions remain significant challenges. Overall, advancements in drug innovation and expanding clinical pipelines are expected to enhance treatment outcomes and create new growth opportunities in the coming years.

Segmentation By Type

  • GLP-2
  • Growth Hormone
  • Glutamine

By Distribution Channel

  • Hospital Pharmacies
  • Online & Retail Pharmacies

By Region

  • North America (By Type, By Distribution Channel, By Country)
    • U.S.
    • Canada
  • Europe (By Type, By Distribution Channel, By Country/Sub-Region)
    • Germany
    • U.K
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia Pacific (By Type, By Distribution Channel, By Country/Sub-Region)
    • India
    • China
    • Japan
    • Australia
    • Southeast Asia
    • South Korea
    • Rest of Asia Pacific
  • Latin America (By Type, By Distribution Channel, By Country/Sub-Region)
    • Brazil
    • Mexico
    • Argentina
    • Colombia
    • Rest of Latin America
  • Middle East & Africa (By Type, By Distribution Channel, By Country/Sub-Region)
    • Turkey
    • Saudi Arabia
    • UAE
    • Rest of the Middle East & Africa

Table of Content

1. Introduction

  • 1.1. Research Scope
  • 1.2. Market Segmentation
  • 1.3. Research Methodology

2. Executive Summary

3. Market Dynamics

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Market Trends

4. Key Insights

  • 4.1. Prevalence of Short Bowel Syndrome, By Key Countries, 2025
  • 4.2. Key Industry Developments - Mergers, Acquisitions, Partnerships, etc.
  • 4.3. Impact of COVID-19 on the Global Market

5. Global Short Bowel Syndrome Market Analysis, Insights and Forecast, 2021-2034

  • 5.1. Market Analysis, Insights and Forecast - By Type
    • 5.1.1. GLP-2
    • 5.1.2. Growth Hormone
    • 5.1.3. Glutamine
  • 5.2. Market Analysis, Insights and Forecast - By Distribution Channel
    • 5.2.1. Hospital Pharmacies
    • 5.2.2. Online & Retail Pharmacies
  • 5.3. Market Analysis, Insights and Forecast - By Region
    • 5.3.1. North America
    • 5.3.2. Europe
    • 5.3.3. Asia Pacific
    • 5.3.4. Latin America
    • 5.3.5. Middle East & Africa

6. North America Short Bowel Syndrome Market Analysis, Insights and Forecast, 2021-2034

  • 6.1. Market Analysis, Insights and Forecast - By Type
    • 6.1.1. GLP-2
    • 6.1.2. Growth Hormone
    • 6.1.3. Glutamine
  • 6.2. Market Analysis, Insights and Forecast - By Distribution Channel
    • 6.2.1. Hospital Pharmacies
    • 6.2.2. Online & Retail Pharmacies
  • 6.3. Market Analysis, Insights and Forecast - By Country
    • 6.3.1. U.S.
    • 6.3.2. Canada

7. Europe Short Bowel Syndrome Market Analysis, Insights and Forecast, 2021-2034

  • 7.1. Market Analysis, Insights and Forecast - By Type
    • 7.1.1. GLP-2
    • 7.1.2. Growth Hormone
    • 7.1.3. Glutamine
  • 7.2. Market Analysis, Insights and Forecast - By Distribution Channel
    • 7.2.1. Hospital Pharmacies
    • 7.2.2. Online & Retail Pharmacies
  • 7.3. Market Analysis, Insights and Forecast - By Country/Sub-region
    • 7.3.1. U.K.
    • 7.3.2. Germany
    • 7.3.3. France
    • 7.3.4. Spain
    • 7.3.5. Italy
    • 7.3.6. Rest of Europe

8. Asia Pacific Short Bowel Syndrome Market Analysis, Insights and Forecast, 2021-2034

  • 8.1. Market Analysis, Insights and Forecast - By Type
    • 8.1.1. GLP-2
    • 8.1.2. Growth Hormone
    • 8.1.3. Glutamine
  • 8.2. Market Analysis, Insights and Forecast - By Distribution Channel
    • 8.2.1. Hospital Pharmacies
    • 8.2.2. Online & Retail Pharmacies
  • 8.3. Market Analysis, Insights and Forecast - By Country/Sub-region
    • 8.3.1. Japan
    • 8.3.2. South Korea
    • 8.3.3. Australia
    • 8.3.4. China
    • 8.3.5. India
    • 8.3.6. Southeast Asia
    • 8.3.7. Rest of Asia Pacific

9. Latin America Short Bowel Syndrome Market Analysis, Insights and Forecast, 2021-2034

  • 9.1. Market Analysis, Insights and Forecast - By Type
    • 9.1.1. GLP-2
    • 9.1.2. Growth Hormone
    • 9.1.3. Glutamine
  • 9.2. Market Analysis, Insights and Forecast - By Distribution Channel
    • 9.2.1. Hospital Pharmacies
    • 9.2.2. Online & Retail Pharmacies
  • 9.3. Market Analysis, Insights and Forecast - By Country/Sub-region
    • 9.3.1. Brazil
    • 9.3.2. Mexico
    • 9.3.3. Argentina
    • 9.3.4. Colombia
    • 9.3.5. Rest of Latin America

10. Middle East & Africa Short Bowel Syndrome Market Analysis, Insights and Forecast, 2021-2034

  • 10.1. Market Analysis, Insights and Forecast - By Type
    • 10.1.1. GLP-2
    • 10.1.2. Growth Hormone
    • 10.1.3. Glutamine
  • 10.2. Market Analysis, Insights and Forecast - By Distribution Channel
    • 10.2.1. Hospital Pharmacies
    • 10.2.2. Online & Retail Pharmacies
  • 10.3. Market Analysis, Insights and Forecast - By Country/Sub-region
    • 10.3.1. Turkey
    • 10.3.2. Saudi Arabia
    • 10.3.3. UAE
    • 10.3.4. Rest of Middle East & Africa

11. Competitive Analysis

  • 11.1. Global Market Share Analysis (2025)
  • 11.2. Company Profiles
    • 11.2.1. Takeda Pharmaceutical Company Limited
      • 11.2.1.1. Overview
      • 11.2.1.2. Products
      • 11.2.1.3. SWOT Analysis
      • 11.2.1.4. Recent Developments
      • 11.2.1.5. Strategies
      • 11.2.1.6. Financials (Based on Availability)
    • 11.2.2. Merck KGaA
      • 11.2.2.1. Overview
      • 11.2.2.2. Products
      • 11.2.2.3. SWOT Analysis
      • 11.2.2.4. Recent Developments
      • 11.2.2.5. Strategies
      • 11.2.2.6. Financials (Based on Availability)
    • 11.2.3. ZEALAND PHARMA
      • 11.2.3.1. Overview
      • 11.2.3.2. Products
      • 11.2.3.3. SWOT Analysis
      • 11.2.3.4. Recent Developments
      • 11.2.3.5. Strategies
      • 11.2.3.6. Financials (Based on Availability)
    • 11.2.4. Ironwood
      • 11.2.4.1. Overview
      • 11.2.4.2. Products
      • 11.2.4.3. SWOT Analysis
      • 11.2.4.4. Recent Developments
      • 11.2.4.5. Strategies
      • 11.2.4.6. Financials (Based on Availability)
    • 11.2.5. Hanmi Pharm. Co., Ltd.
      • 11.2.5.1. Overview
      • 11.2.5.2. Products
      • 11.2.5.3. SWOT Analysis
      • 11.2.5.4. Recent Developments
      • 11.2.5.5. Strategies
      • 11.2.5.6. Financials (Based on Availability)
    • 11.2.6. Nestle
      • 11.2.6.1. Overview
      • 11.2.6.2. Products
      • 11.2.6.3. SWOT Analysis
      • 11.2.6.4. Recent Developments
      • 11.2.6.5. Strategies
      • 11.2.6.6. Financials (Based on Availability)
    • 11.2.7. Jaguar Health
      • 11.2.7.1. Overview
      • 11.2.7.2. Products
      • 11.2.7.3. SWOT Analysis
      • 11.2.7.4. Recent Developments
      • 11.2.7.5. Strategies
      • 11.2.7.6. Financials (Based on Availability)
    • 11.2.8. EnteraBio Ltd.
      • 11.2.8.1. Overview
      • 11.2.8.2. Products
      • 11.2.8.3. SWOT Analysis
      • 11.2.8.4. Recent Developments
      • 11.2.8.5. Strategies
      • 11.2.8.6. Financials (Based on Availability)
    • 11.2.9. OxThera
      • 11.2.9.1. Overview
      • 11.2.9.2. Products
      • 11.2.9.3. SWOT Analysis
      • 11.2.9.4. Recent Developments
      • 11.2.9.5. Strategies
      • 11.2.9.6. Financials (Based on Availability)

List of Tables

  • Table 1: Global Short Bowel Syndrome Market Revenue (USD billion) Forecast, by Type, 2021-2034
  • Table 2: Global Short Bowel Syndrome Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 3: Global Short Bowel Syndrome Market Revenue (USD billion) Forecast, by Region, 2021-2034
  • Table 4: North America Short Bowel Syndrome Market Revenue (USD billion) Forecast, by Type, 2021-2034
  • Table 5: North America Short Bowel Syndrome Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 6: North America Short Bowel Syndrome Market Revenue (USD billion) Forecast, By Country, 2021-2034
  • Table 7: Europe Short Bowel Syndrome Market Revenue (USD billion) Forecast, by Type, 2021-2034
  • Table 8: Europe Short Bowel Syndrome Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 9: Europe Short Bowel Syndrome Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 10: Asia Pacific Short Bowel Syndrome Market Revenue (USD billion) Forecast, by Type, 2021-2034
  • Table 11: Asia Pacific Short Bowel Syndrome Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 12: Asia Pacific Short Bowel Syndrome Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 13: Latin America Short Bowel Syndrome Market Revenue (USD billion) Forecast, by Type, 2021-2034
  • Table 14: Latin America Short Bowel Syndrome Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 15: Latin America Short Bowel Syndrome Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 16: Middle East & Africa Short Bowel Syndrome Market Revenue (USD billion) Forecast, by Type, 2021-2034
  • Table 17: Middle East & Africa Short Bowel Syndrome Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 18: Middle East & Africa Short Bowel Syndrome Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034

List of Figures

  • Figure 1: Global Short Bowel Syndrome Market Revenue Breakdown (USD billion, %) by Region, 2025 & 2034
  • Figure 2: Global Short Bowel Syndrome Market Value Share (%), by Type, 2025 & 2034
  • Figure 3: Global Short Bowel Syndrome Market Value Share (%), by Distribution Channel, 2025 & 2034
  • Figure 4: Global Short Bowel Syndrome Market Value Share (%), by Region, 2025 & 2034
  • Figure 5: North America Short Bowel Syndrome Market Value (USD billion), by Type, 2025 & 2034
  • Figure 6: North America Short Bowel Syndrome Market Value Share (%), by Type, 2025
  • Figure 7: North America Short Bowel Syndrome Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 8: North America Short Bowel Syndrome Market Value Share (%), by Distribution Channel, 2025
  • Figure 9: North America Short Bowel Syndrome Market Value (USD billion), By Country, 2025 & 2034
  • Figure 10: North America Short Bowel Syndrome Market Value Share (%), By Country, 2025
  • Figure 11: Europe Short Bowel Syndrome Market Value (USD billion), by Type, 2025 & 2034
  • Figure 12: Europe Short Bowel Syndrome Market Value Share (%), by Type, 2025
  • Figure 13: Europe Short Bowel Syndrome Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 14: Europe Short Bowel Syndrome Market Value Share (%), by Distribution Channel, 2025
  • Figure 15: Europe Short Bowel Syndrome Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 16: Europe Short Bowel Syndrome Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 17: Asia Pacific Short Bowel Syndrome Market Value (USD billion), by Type, 2025 & 2034
  • Figure 18: Asia Pacific Short Bowel Syndrome Market Value Share (%), by Type, 2025
  • Figure 19: Asia Pacific Short Bowel Syndrome Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 20: Asia Pacific Short Bowel Syndrome Market Value Share (%), by Distribution Channel, 2025
  • Figure 21: Asia Pacific Short Bowel Syndrome Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 22: Asia Pacific Short Bowel Syndrome Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 23: Latin America Short Bowel Syndrome Market Value (USD billion), by Type, 2025 & 2034
  • Figure 24: Latin America Short Bowel Syndrome Market Value Share (%), by Type, 2025
  • Figure 25: Latin America Short Bowel Syndrome Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 26: Latin America Short Bowel Syndrome Market Value Share (%), by Distribution Channel, 2025
  • Figure 27: Latin America Short Bowel Syndrome Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 28: Latin America Short Bowel Syndrome Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 29: Middle East & Africa Short Bowel Syndrome Market Value (USD billion), by Type, 2025 & 2034
  • Figure 30: Middle East & Africa Short Bowel Syndrome Market Value Share (%), by Type, 2025
  • Figure 31: Middle East & Africa Short Bowel Syndrome Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 32: Middle East & Africa Short Bowel Syndrome Market Value Share (%), by Distribution Channel, 2025
  • Figure 33: Middle East & Africa Short Bowel Syndrome Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 34: Middle East & Africa Short Bowel Syndrome Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 35: Global Short Bowel Syndrome Market Share (%), By Company, 2025